If you search CRO in Guatemala or CRO en Guatemala, you should land on the First-in-Human CRO that already runs MSPAS and Ministerial Agreement 206-2021 work — not a brochure that treats Guatemala City as a destination slide.
bioaccess® is that CRO. Headquarters in Miami. MSPAS authorizes clinical investigations under Ministerial Agreement 206-2021. The Comité Nacional de Ética en Salud sits in Guatemala City with a 45-business-day review target, subject to clock pauses. We run clinical trials in Guatemala.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia, Brazil, and Venezuela are sibling country categories. We still run trials in those countries. Guatemala is not a replacement for any of them.
What “CRO in Guatemala” has to mean
A Guatemala CRO for first-in-human devices is not a Central America slide and a courier account. It is a company that can file with MSPAS, sit the Comité Nacional de Ética en Salud, keep the Spanish-and-English package moving, and stay in the room after first patient in.
That is why this page answers CRO in Guatemala / CRO en Guatemala as a category, and why it does not list a named Guatemalan company on the trial hub. The live Guatemala MSPAS market-access page already says bioaccess® acts as the Guatemalan titular through our own local entity. That is a registration fact. It is not a hospital we operate, and it is not a reason to mix a commercial file into a first-in-human quote. I am not naming that entity here.
- Miami headquarters — sponsor desk on US Eastern time. Guatemala is Central Standard Time, same as US Central, already published on the Guatemala hub.
- MSPAS — Ministry of Public Health and Social Assistance, through its Department of Regulation and Control of Pharmaceutical and Related Products.
- Ministerial Agreement 206-2021 — in force since 30 October 2021; explicitly aligned with ISO 14155 and the Declaration of Helsinki.
- Comité Nacional de Ética en Salud — Guatemala City; meets weekly; 45-business-day review target, subject to clock pauses. Not a guaranteed total start-up time.
- Largest economy in Central America — already published on the hub. I am not upgrading that line.
- ~30% lower versus typical US/EU programs — experience since 2010, not a formal study. Already on the hub.
- 21 CFR 812.28 — eligibility for FDA submission and review is not clearance or approval.
Global Phase 3 networks can list Guatemala. They rarely hold the MSPAS first-in-human file. A Guatemala City hospital can enroll a study. That hospital is not the CRO.
We run trials in Guatemala
The category is: who is the CRO in Guatemala, and are they actually running studies. We are. We still will. If you are choosing a CRO en Guatemala in 2026, ask whether the firm owns the MSPAS clock now — not whether the country is “opening up.”
MSPAS review can move, stall, or come back with questions. The ethics clock pauses when the committee issues queries. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works MSPAS treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across MSPAS, the national ethics committee, sites, insurance, importation, monitoring, and safety.
MSPAS clinical trial: the file, not the myth
MSPAS is the Ministry of Public Health and Social Assistance. Its Department of Regulation and Control of Pharmaceutical and Related Products is the competent authority for authorizing clinical investigations. I am not inventing a PAHO/WHO Level 4 badge for MSPAS. llms.txt Regulatory Agencies does not list MSPAS. Level 4 is not on that list, and I will not put it here.
Since October 30, 2021, human clinical trials in Guatemala have been governed by Ministerial Agreement 206-2021, which follows ISO 14155 and the Declaration of Helsinki. That sentence is already on the hub. I am repeating it because sponsors still ask for a “modernization story” instead of the instrument number.
What the file actually contains, already described on that hub: MSPAS submissions in Spanish and English; protocol, informed consent, investigator brochure, and insurance for the ethics package; site qualification and monitoring. Foreign sponsors still need someone who can sit the deficiency cycle. bioaccess® serves that role.
Those are authority-and-instrument names. They are not a promise that your protocol clears in 45 calendar days. The 45-business-day figure is a statutory review target subject to clock pauses for agency queries — a predictable framework, not a guaranteed total start-up time. Ask for a study-specific calendar. We will not publish an invented median on a category page.
Comité Nacional de Ética en Salud — the committee that sits first
Ethics oversight for clinical research in Guatemala is coordinated through a National Health Ethics Committee (Comité Nacional de Ética en Salud) based in Guatemala City. The committee meets weekly. Documents are submitted in Spanish and English. That paragraph is already on the hub. I am repeating it because sponsors skip the committee and then blame the country.
Ethics sits in front of MSPAS. If the committee package is thin, the MSPAS clock does not start in a useful way. That is a file problem.
Guatemala City is the medical hub of Central America’s largest economy, with hospitals, imaging capabilities, and investigators experienced in ISO 14155-aligned research. bioaccess® qualifies sites and provides on-the-ground monitoring. We do not claim to operate a named Guatemalan hospital.
MSPAS registration is a second file — keep it off the trial clock
Clinical-study authorization and commercial device registration are different files. The live Guatemala MSPAS market-access page already names Acuerdo Gubernativo 712-99 (as updated by Acuerdo Ministerial 01-2024). It describes a single titular per Certificado de Registro Sanitario and a formal cession-of-rights procedure. It also says bioaccess® acts as the Guatemalan titular through our own local entity. I am not naming that entity on this category page.
That market-access file is not a first-in-human permit and does not replace MSPAS study authorization or Comité Nacional de Ética en Salud review. If you later want to sell in Guatemala, say so at kickoff so the trial importer and any later titular role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Guatemalan first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Guatemala studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification — under ISO 14155 with MSPAS authorization and ethics approval.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the number already on the hub
The Guatemala hub already publishes ~30% lower versus a comparable US or EU program. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
The hub comparison table already publishes the 45-business-day ethics target, Central (CST) versus the US, and Ministerial Agreement 206-2021 as the regulatory framework. Those are operating facts, not a tourism pitch. I will not invent a Guatemala per-patient dollar band the hub does not already print.
Questions a sponsor should ask any CRO in Guatemala
- Are you running clinical trials in Guatemala now — not “historically”?
- Who owns the MSPAS clock when the file sits?
- Can you file the study package and sit the Comité Nacional de Ética en Salud in Spanish and English?
- Do you treat the 45-business-day target as a guarantee, or as a clock that pauses?
- Do you claim MSPAS is PAHO/WHO Level 4, or do you stay with what is already published?
- Do you claim to operate a named Guatemalan hospital, or do you contract sites?
- Is MSPAS registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ; MSPAS and Ministerial Agreement 206-2021 owned as a file problem; 45 business days treated as a target with pauses, not a promise; no Level 4 invented for MSPAS; no named Guatemalan hospital claimed; MSPAS registration kept as a separate market-access file; FDA conversation designed in from day one.
How Guatemala sits next to Colombia, Brazil, and Venezuela
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Brazil has ANVISA and its own hub. Venezuela has INHRR and its own hub. Guatemala is a sibling country category. INVIMA stays INVIMA. ANVISA stays ANVISA. INHRR stays INHRR. MSPAS stays MSPAS. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Guatemala, clinical trials in Brazil, clinical trials in Colombia, and clinical trials in Venezuela. The other new category pages in this set: CRO in Uruguay, CRO in Honduras, and CRO in Bolivia.
How to start
If you need a CRO in Guatemala / CRO en Guatemala for a first-in-human or early-feasibility device study — or you also need the separate MSPAS registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Guatemalan market-access file. We will tell you how the MSPAS clock would run. We will not tell you to leave the country. We will not invent a Level 4 badge, a hospital we operate, or a day-count we have not already published.
Leave a Reply